Delivering quality therapy since 1901

Press releases

 

 

Molecular Biology Laboratory inaugurated in the Hungarian city of Debrecen712<img alt="" src="/en-US/PublishingImages/RG%20eng%20logo.jpg" style="BORDER&#58;0px solid;" />2018.00000000000<p>​<span lang="EN-GB"><strong>Lajos Kósa, Hungary’s Minister without Portfolio, responsible for the development of Cities of County Rank, Dr László Papp, Mayor of Debrecen, Erik Bogsch, Gedeon Richter Plc’s Chairman and Gábor Orbán, Gedeon Richter Plc’s CEO inaugurated Richter’s new Molecular Biology Laboratory at a ceremony held in the Hungarian city of Debrecen. The facility was built with a total budget of HUF 4.89 billion as part of a joint consortium tender entitled “Innovative pharmaceutical research and development project to improve competitiveness in the market”. The total investment cost of the laboratory infrastructure and technological equipment (as a part of the project) was close to HUF 1.7 billion, of which HUF 713 million was funded by the awarded aid. </strong></span></p>2018-03-28T22:00:00Z3/29/2018 2:09:12 PM2782http://rgextend.richter.hu/en-US/pressroom/press-release/Pages/press-releaseshtmlFalseaspx
Gedeon Richter Plc’s antipsychotic drug wins the 2017 Innovation Grand Prize275<img alt="" src="/en-US/PublishingImages/RG%20eng%20logo.jpg" style="BORDER&#58;0px solid;" /><p><strong>​</strong><span lang="EN-GB"><strong>The Hungarian Innovation Foundation has awarded Gedeon Richter Plc the Innovation Grand Prize for its tender proposal entitled “Cariprazine</strong></span><span lang="EN-GB"><strong> (Vraylar®/Reagila®), a new original Hungarian drug on the global market”. The Innovation Grand Prize was presented to Gedeon Richter Plc’s Chairman Erik Bogsch by János Latorcai, Vice Speaker of the Hungarian National Assembly and József Pálinkás, President of the National Research, Development and Innovation Office. </strong></span></p>2018-03-27T22:00:00Z3/28/2018 11:51:37 AM477http://rgextend.richter.hu/en-US/pressroom/press-release/Pages/press-releaseshtmlFalseaspx
Peter D.J. Grootenhuis, Ph.D. is Awarded the 2018 IUPAC-Richter Prize2372<img alt="" src="/en-US/PublishingImages/RG%20eng%20logo.jpg" style="BORDER&#58;0px solid;" />2018.00000000000​<span lang="EN-GB"><strong>The 2018 IUPAC-Richter Prize in Medicinal Chemistry has been awarded to Peter D.J. Grootenhuis. </strong></span><br><br>2018-01-25T23:00:00Z1/26/2018 1:00:32 PM1101http://rgextend.richter.hu/en-US/pressroom/press-release/Pages/press-releaseshtmlFalseaspx
Allergan and Richter Announce Positive Topline Results from Phase III Study of Cariprazine for the Treatment of Bipolar I Depression414<img alt="" src="/en-US/PublishingImages/RG%20eng%20logo.jpg" style="BORDER&#58;0px solid;" />2017.00000000000<p>​<span lang="EN-US" style="line-height&#58;115%;font-family&#58;&quot;arial&quot;,&quot;sans-serif&quot;;font-size&#58;11pt;"><font color="#000000" face="Arial">Allergan plc (NYSE&#58; AGN), a leading global pharmaceutical company, and Gedeon Richter Plc., today announced positive topline results for a phase III study of cariprazine for the treatment of adults with major depressive episodes associated with bipolar I disorder (bipolar I depression). This is the second positive pivotal trial of cariprazine for this investigational use. </font></span></p>2017-12-17T23:00:00Z12/18/2017 1:12:04 PM1150http://rgextend.richter.hu/en-US/pressroom/press-release/Pages/press-releaseshtmlFalseaspx
European CHMP Issues Positive Opinion for Cariprazine for the Treatment of Schizophrenia1092<img alt="" src="/en-US/PublishingImages/RG%20eng%20logo.jpg" style="BORDER&#58;0px solid;" />2017.00000000000<p>​Gedeon Richter Plc. (&quot;Richter&quot;) announces that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion on the company's application for cariprazine, a novel antipsychotic for the treatment of schizophrenia in adult patients. The marketing authorization application has been submitted to EMA in March 2016. Subject to approval by the European Commission, Richter is expected to receive in two months a marketing authorization for cariprazine valid for all European Union Member States.</p>2017-05-18T22:00:00Z5/19/2017 12:22:14 PM3468http://rgextend.richter.hu/en-US/pressroom/press-release/Pages/press-releaseshtmlFalseaspx
Richter and DM Bio agreement on technology transfer and license-in of biosimilar Trastuzumab1920<img alt="" src="/en-US/PublishingImages/RG%20eng%20logo.jpg" style="BORDER&#58;0px solid;" />2016.00000000000<p>​Gedeon Richter Plc. (&quot;Richter&quot;) today announces that it has signed a technology transfer and license-in agreement with DM Bio (&quot;DM Bio&quot;) in respect of the development and commercialization of DM Bio's biosimilar monoclonal antibody, Trastuzumab.</p>2016-10-18T22:00:00Z10/21/2016 12:18:33 PM3575http://rgextend.richter.hu/en-US/pressroom/press-release/Pages/press-releaseshtmlFalseaspx
Richter and Allergan Provide Update on Cariprazine Program1663<img alt="" src="/en-US/PublishingImages/RG%20eng%20logo.jpg" style="BORDER&#58;0px solid;" />2016.00000000000<p>​</p><p style="text-align&#58;justify;"><strong>BUDAPEST, Hungary</strong> and <strong>DUBLIN, Ireland</strong> –&#160;Allergan plc&#160;(NYSE&#58; AGN), a leading global pharmaceutical company and Gedeon Richter Plc., today provided a clinical and regulatory update on cariprazine. For more than a decade both companies have conducted&#160; over 20 clinical trials enrolling thousands of patients worldwide to evaluate the&#160; efficacy and safety of cariprazine for patients suffering from a broad range of mental health illnesses.&#160; </p><p style="text-align&#58;justify;">&#160;</p>2016-08-04T22:00:00Z8/5/2016 5:55:36 AM2059http://rgextend.richter.hu/en-US/pressroom/press-release/Pages/press-releaseshtmlFalseaspx
Richter announces the acquisition of Finox Holding for a consideration of CHF190 million675<img alt="" src="/en-US/PublishingImages/RG%20eng%20logo.jpg" style="BORDER&#58;0px solid;" />2016.000000000002016-06-29T22:00:00Z6/30/2016 8:44:52 AM4923http://rgextend.richter.hu/en-US/pressroom/press-release/Pages/press-releaseshtmlFalseaspx
Allergan and Richter Announce Positive Phase III Results for Ulipristal Acetate 5 and 10 mg in the Treatment of Uterine Fibroids1318<img alt="" src="/en-US/PublishingImages/RG%20eng%20logo.jpg" style="BORDER&#58;0px solid;" />2016.00000000000<p>​DUBLIN, Ireland and BUDAPEST, Hungary – 9 May 2016, --&#160;Allergan Plc (NYSE&#58; AGN) and Gedeon Richter Plc. today announced positive results from Venus I, one of two pivotal Phase III clinical trials evaluating the efficacy and safety of ulipristal acetate in women with uterine fibroids. </p>2016-05-08T22:00:00Z5/9/2016 6:37:46 AM1580http://rgextend.richter.hu/en-US/pressroom/press-release/Pages/press-releaseshtmlFalseaspx
EMA started the evaluation of Richter’s marketing authorisation application for cariprazine for the treatment of schizophrenia1178<img alt="" src="/en-US/PublishingImages/RG%20eng%20logo.jpg" style="BORDER&#58;0px solid;" />2016.00000000000<p>​Gedeon Richter Plc. (&quot;Richter&quot;) today announced that the European Medicines Agency (EMA) has accepted Richter's regulatory submission for cariprazine, a novel antipsychotic for the treatment of schizophrenia in adult patients. Cariprazine was discovered by Richter scientists and is licensed to Allergan (earlier Forest / Actavis), in the U.S. and Canada. Following its FDA approval in September 2015, the product has been recently launched in the USA under the trademark of VRAYLAR<sup>TM</sup> for the treatment of both schizophrenia and bipolar mania. </p>2016-03-28T22:00:00Z3/29/2016 5:51:47 AM2705http://rgextend.richter.hu/en-US/pressroom/press-release/Pages/press-releaseshtmlFalseaspx